Glenmark Pharmaceuticals Ltd
GLENMARKGlenmark Pharmaceuticals Ltd's earnings have outrun its stock. EPS grew +30.0% in a year against a +8.0% price move.
Biggest watch item: margins are the best this company has ever printed — every ratio flatters at record profitability, so the whole story leans on margins holding.
The price is in a confirmed uptrend (60 weeks in) while the P/E sits at the 56th percentile of its own 10-year range. Underneath, the last four quarters read improving — profit +927.7% year on year, and 116% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Glenmark Pharmaceuticals Ltd trades at ₹2,234, in a confirmed uptrend and 60 weeks into that stage. That is +6.0% against its own 200-day average. It sits at 71% of a 52-week range of ₹1,812 to ₹2,406. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (13 weeks and counting).
Today the stock is in a confirmed uptrend — week 60 of stage 2, confirmed. At ₹2,234 it trades +6.0% versus its 200-day average and sits at 71% of its 52-week range (₹1,812–₹2,406).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +203% while the NIFTY 500 moved +282% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (13 weeks and counting; last ahead the week of 2026-06-04) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Glenmark Pharmaceuticals Ltd trades at 20.2× P/E, mid-range by its own standards (56th percentile). Its long-run median P/E is 18.6×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 20.2× is mid-range by its own standards (56th percentile), against a long-run median of 18.6× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +30.0% against a +8.0% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the +29.8%/yr price move, ~+27.1%/yr came from earnings growth and ~+2.7 pp from the multiple (expanding); over 10y, of the +10.0%/yr price move, ~+14.7%/yr came from earnings growth and ~−4.7 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Glenmark Pharmaceuticals Ltd reads as mixed on its fundamental arc. Mixed — no clean majority across the growth curves, ROCE holding at 18.6% — the per-curve reads carry the story. The read is built from 12 quarters across 3 curves, on partial evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +27.5% | +13.6% | +9.2% | +8.4% |
| Profit | +30.1% | +53.4% | +7.0% | +6.2% |
| EPS | +30.0% | +66.1% | +7.0% | +6.2% |
| Share price | +8.0% | +40.9% | +29.8% | +10.0% |
4-Factor Sector Score
65.8/100 — rank 5 of 43 in Pharma - Formulators · 100% evidence confidence
Glenmark Pharmaceuticals Ltd scores 65.8 out of 100 against the 43 companies it is compared with in Pharma - Formulators, ranking 5. Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -10.3% and the one-year return is 4.1%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
The four contributions add to the total exactly: 30.5 + 17.5 + 12.2 + 5.6 = 65.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Glenmark Pharmaceuticals Ltd reported ₹4,018 Cr of revenue in the Jun 26 quarter, +23.1% year on year. That is the 10th straight quarter of year-on-year growth. Over 10 years it has compounded at 8.4% a year. The last full year, FY26, came in at ₹16,983 Cr. The last four reported quarters add to ₹17,737 Cr.
FY26 revenue came in at ₹16,983 Cr (+27.5% on the year), capping 10 years at 8.4% compound. The latest quarter (Jun 26) printed ₹4,018 Cr, +23.1% year on year — the 10th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +32.5% growth against the decade's 8.4% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +32.9% over the last 4 quarters against +21.5%/yr over the last 8 — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Glenmark Pharmaceuticals Ltd's operating margin is 20.0% in the Jun 26 quarter, +2.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 13 fiscal years the operating margin has ranged 10.0% to 27.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 20.0%, +2.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 10.0%–27.0%, and FY26's 27.0% is the top of that band — a record year.
Why the margin moved: operating margin went +2.3 pp year on year while gross margin went +0.1 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Glenmark Pharmaceuticals Ltd earned ₹483 Cr of net profit in the Jun 26 quarter, +927.7% year on year. It is the 4th consecutive quarter of growth. Full-year FY26 profit was ₹1,362 Cr. The 10-year compound rate is 6.2%. That is 12.0% of the quarter's revenue. The same quarter a year earlier earned ₹47.0 Cr.
Jun 26 profit was ₹483 Cr, +927.7% year on year — the 4th consecutive quarter of growth. On the full year, FY26 printed ₹1,362 Cr (+30.1%), and the 10-year compound rate is 6.2%.
Why profit moved: revenue contributed +23.1% and the margin +2.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +2,110.2% vs revenue +32.5%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 116% of Glenmark Pharmaceuticals Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹3,445 Cr of operating cash against ₹1,362 Cr of profit. After ₹2,075 Cr of capital spending, ₹1,370 Cr was left as free cash.
FY26: operating cash of ₹3,445 Cr against reported profit of ₹1,362 Cr, leaving free cash of ₹1,370 Cr after ₹2,075 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 116% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 116%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle.
Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Glenmark Pharmaceuticals Ltd's cash conversion cycle runs 83 days in FY26, down from 90 days in FY21. Capital spending ran ₹1,853 Cr over the last 3 years. At FY26 sales of ₹16,983 Cr each day of that cycle holds about ₹46.5 Cr, so roughly ₹3,862 Cr sits inside the business at any moment.
FY26: debtors at 107 days, inventory at 264 days — roughly 8.7 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 83 days, tighter than FY21's 90.
The full loop: cash goes out to suppliers and production on day 0; stock waits 264 days to sell; customers pay about 107 days after that; and suppliers themselves are paid at 288 days — netting out to the 83-day cycle.
In money terms: at FY26 sales of ₹16,983 Cr, each day of the cycle holds about ₹46.5 Cr — so the 83-day loop keeps roughly ₹3,862 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹1,853 Cr over the last 3 fiscal years against ₹1,641 Cr of depreciation — building somewhat ahead of wear-and-tear. Capital work-in-progress stands at ₹428 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Glenmark Pharmaceuticals Ltd earns a ROCE of 40% in FY26. That is up from a trough of 10% in FY23. Return on invested capital clears the cost of that capital by +17.9 percentage points, so growth here adds value rather than only size. The wiring behind it is 8.0% net margin on 0.85× asset turns.
FY26 ROCE is 40%, recovered from a FY23 trough of 10% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 8.0% net margin × 0.85× asset turns × 1.89× balance-sheet leverage ≈ 12.9% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 29.9% − 12.0% = a +17.9 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Glenmark Pharmaceuticals Ltd carries total debt of ₹594 Cr against shareholder equity of ₹10,512 Cr as of Mar 26, a debt-to-equity of 0.06 — effectively unlevered. On the annual view that ratio went from 0.42 in FY22 to 0.06 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹594 Cr against shareholder equity of ₹10,512 Cr — a debt-to-equity of 0.06. On the annual view, debt-to-equity went from 0.42 (FY22) to 0.06 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions added 4.7 points of Glenmark Pharmaceuticals Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 18.6% of the company. Foreign institutions moved −0.1 points over the same window, to 20.9%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: +4.7 points over 8 quarters to 18.6%; Foreign institutions: −0.1 points over 8 quarters to 20.9%; Promoters: +0.0 points over 8 quarters to 46.6%.
Why the register moved: domestic institutions drove it (+4.7 points) — steady accumulation by institutions reading the same numbers this page reads.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Glenmark Pharmaceuticals Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Lupin LtdLUPIN | 74.1/100Favorable setup89% evidence | TURNING | 29.7/35 Revenue 23.1% · PAT 62% · OPM change 10 pp 88% evidence | 21.0/25 ROCE 29.9% · OPM 33% 100% evidence | 16.3/20 P/E 19.4× · PEG 0.54 65% evidence | 7.1/20 RS sector -7.4% · RS bench 9% · 1Y 23.8%2 of 12 weeks ahead 100% evidence |
| Exact sum: 29.7 + 21 + 16.3 + 7.1 = 74.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Kwality Pharmaceuticals Ltd539997 | 72.8/100Favorable setup78% evidence | LEADER | 29.0/35 Revenue 35.7% · PAT 71.8% · OPM change 3 pp 83% evidence | 17.8/25 ROCE 24.2% · OPM 25% 76% evidence | 6.4/20 P/E 39.4× · PEG — 50% evidence | 19.6/20 RS sector 51.5% · RS bench 73.2% · 1Y 121.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 29 + 17.8 + 6.4 + 19.6 = 72.8 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3Caplin Point Laboratories LtdCAPLIPOINT | 68.3/100Favorable setup96% evidence | LEADER | 19.6/35 Revenue 12.9% · PAT 20.1% · OPM change 1 pp 88% evidence | 18.9/25 ROCE 24.6% · OPM 34% 100% evidence | 12.1/20 P/E 29.8× · PEG 0.99 100% evidence | 17.7/20 RS sector 5.7% · RS bench 24.1% · 1Y 23.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.6 + 18.9 + 12.1 + 17.7 = 68.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Bliss GVS Pharma LtdBLISSGVS | 66.9/100Favorable setup78% evidence | LEADER | 27.2/35 Revenue 14.3% · PAT 48.4% · OPM change 6 pp 83% evidence | 13.2/25 ROCE 16.9% · OPM 17% 76% evidence | 6.9/20 P/E 37.5× · PEG — 50% evidence | 19.6/20 RS sector 64.6% · RS bench 87.2% · 1Y 203.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 27.2 + 13.2 + 6.9 + 19.6 = 66.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Glenmark Pharmaceuticals Ltdthis pageGLENMARK | 65.8/100Favorable setup100% evidence | ASLEEP | 30.5/35 Revenue 32.9% · PAT 100% · OPM change 2 pp 100% evidence | 17.5/25 ROCE 39.8% · OPM 20% 100% evidence | 12.2/20 P/E 20.2× · PEG 1.43 100% evidence | 5.6/20 RS sector -10.3% · RS bench 5.6% · 1Y 4.1%3 of 12 weeks ahead 100% evidence |
| Exact sum: 30.5 + 17.5 + 12.2 + 5.6 = 65.8 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -10.3% and the one-year return is 4.1%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 6Emcure Pharmaceuticals LtdEMCURE | 65.4/100Favorable setup71% evidence | LEADER | 24.6/35 Revenue 16.6% · PAT 32.9% · OPM change 0 pp 83% evidence | 17.9/25 ROCE 24% · OPM 19% 76% evidence | 9.4/20 P/E 39.3× · PEG — 15% evidence | 13.5/20 RS sector 7.1% · RS bench 25.6% · 1Y 39.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 24.6 + 17.9 + 9.4 + 13.5 = 65.4 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 7Corona Remedies LtdCORONA | 64.5/100Mixed-positive evidence73% evidence | BREAKING OUT | 23.7/35 Revenue 18% · PAT 19.3% · OPM change 2 pp 100% evidence | 19.4/25 ROCE 33.3% · OPM 22% 100% evidence | 11.4/20 P/E 60.5× · PEG 1.18 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y —9 of 12 weeks ahead 0% evidence |
| Exact sum: 23.7 + 19.4 + 11.4 + 10 = 64.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Ajanta Pharma LtdAJANTPHARM | 61.4/100Mixed-positive evidence100% evidence | BREAKING OUT | 21.9/35 Revenue 20.2% · PAT 22.2% · OPM change -1 pp 100% evidence | 18.9/25 ROCE 34.5% · OPM 26% 100% evidence | 5.7/20 P/E 38.2× · PEG 2.31 100% evidence | 14.9/20 RS sector 3.1% · RS bench 21% · 1Y 24.5%7 of 12 weeks ahead 100% evidence |
| Exact sum: 21.9 + 18.9 + 5.7 + 14.9 = 61.4 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 9Zydus Lifesciences LtdZYDUSLIFE | 61.2/100Mixed-positive evidence96% evidence | LEADER | 17.1/35 Revenue 16.8% · PAT 9.7% · OPM change 1 pp 88% evidence | 17.8/25 ROCE 21.1% · OPM 34% 100% evidence | 13.9/20 P/E 20.7× · PEG 1.4 100% evidence | 12.4/20 RS sector -3.3% · RS bench 13.8% · 1Y 15.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 17.8 + 13.9 + 12.4 = 61.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Rubicon Research LtdRUBICON | 60.9/100Mixed-positive evidence69% evidence | BREAKING OUT | 23.9/35 Revenue 36.6% · PAT 84.3% · OPM change 3 pp 88% evidence | 21.4/25 ROCE 28.4% · OPM 23% 100% evidence | 5.6/20 P/E 99.9× · PEG 2.65 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y —12 of 12 weeks ahead 0% evidence |
| Exact sum: 23.9 + 21.4 + 5.6 + 10 = 60.9 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 11Ipca Laboratories LtdIPCALAB | 58.9/100Mixed-positive evidence78% evidence | BREAKING OUT | 22.2/35 Revenue 7.9% · PAT 51% · OPM change 1 pp 83% evidence | 15.3/25 ROCE 17% · OPM 20% 76% evidence | 11.0/20 P/E 37.6× · PEG — 50% evidence | 10.4/20 RS sector -2% · RS bench 15.1% · 1Y 15.8%7 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 15.3 + 11 + 10.4 = 58.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Marksans Pharma LtdMARKSANS | 58.3/100Mixed-positive evidence83% evidence | TURNING | 19.9/35 Revenue 12.5% · PAT 9.7% · OPM change 5 pp 88% evidence | 18.1/25 ROCE 18.8% · OPM 23% 100% evidence | 11.5/20 P/E 28× · PEG 1.41 65% evidence | 8.8/20 RS sector -18.1% · RS bench 30.6% · 1Y 13.4%11 of 11 weeks ahead 70% evidence |
| Exact sum: 19.9 + 18.1 + 11.5 + 8.8 = 58.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Wockhardt LtdWOCKPHARMA | 58.1/100Mixed-positive evidence71% evidence | LEADER | 22.6/35 Revenue 12% · PAT 100% · OPM change 14 pp 65% evidence | 9.0/25 ROCE 7.5% · OPM 23% 100% evidence | 8.7/20 P/E 112× · PEG — 15% evidence | 17.8/20 RS sector 10.5% · RS bench 29.2% · 1Y 16.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.6 + 9 + 8.7 + 17.8 = 58.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Accent Microcell LtdACCENTMIC | 58.1/100Mixed-positive evidence63% evidence | LEADER | 17.5/35 Revenue — · PAT — · OPM change -1 pp 26% evidence | 16.9/25 ROCE 24.9% · OPM 16% 95% evidence | 9.7/20 P/E 27.8× · PEG — 50% evidence | 14.0/20 RS sector 18.5% · RS bench 37.8% · 1Y 85.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 17.5 + 16.9 + 9.7 + 14 = 58.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Amrutanjan Health Care LtdAMRUTANJAN | 55.9/100Mixed-positive evidence77% evidence | ASLEEP | 20.9/35 Revenue 11.3% · PAT 11.8% · OPM change 4 pp 83% evidence | 17.0/25 ROCE 24.8% · OPM 17% 95% evidence | 14.2/20 P/E 23.1× · PEG — 50% evidence | 3.8/20 RS sector -24.6% · RS bench -18.4% · 1Y -24.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 20.9 + 17 + 14.2 + 3.8 = 55.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16RPG Life Sciences LtdRPGLIFE | 54.0/100Mixed-positive evidence93% evidence | LEADER | 11.8/35 Revenue 11.9% · PAT -34.1% · OPM change 1 pp 100% evidence | 17.3/25 ROCE 25.7% · OPM 22% 100% evidence | 10.2/20 P/E 39.2× · PEG 1.43 65% evidence | 14.7/20 RS sector 2.5% · RS bench 20.8% · 1Y 11.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 11.8 + 17.3 + 10.2 + 14.7 = 54 · Decision use: Price leads the evidence: RS versus the benchmark is 20.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 17Kilitch Drugs (India) LtdKILITCH | 53.7/100Mixed-positive evidence83% evidence | BREAKING OUT | 18.2/35 Revenue 19.8% · PAT 16% · OPM change 1 pp 83% evidence | 10.7/25 ROCE 14.4% · OPM 25% 95% evidence | 14.0/20 P/E 21.6× · PEG — 50% evidence | 10.8/20 RS sector -10.2% · RS bench 6.2% · 1Y -15%10 of 12 weeks ahead 100% evidence |
| Exact sum: 18.2 + 10.7 + 14 + 10.8 = 53.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Alkem Laboratories LtdALKEM | 53.6/100Mixed-positive evidence78% evidence | TURNING | 19.8/35 Revenue 13.5% · PAT 6.1% · OPM change 2 pp 83% evidence | 16.3/25 ROCE 21.2% · OPM 14% 76% evidence | 11.9/20 P/E 28.2× · PEG — 50% evidence | 5.6/20 RS sector -12.9% · RS bench 3% · 1Y 14.8%2 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 16.3 + 11.9 + 5.6 = 53.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19FDC LtdFDC | 52.2/100Mixed-positive evidence90% evidence | TURNING | 16.7/35 Revenue 3% · PAT 4.9% · OPM change 7 pp 88% evidence | 14.8/25 ROCE 16.7% · OPM 18% 100% evidence | 15.7/20 P/E 22.5× · PEG 0.93 100% evidence | 5.0/20 RS sector -25.2% · RS bench -0.4% · 1Y -16.2%6 of 10 weeks ahead 70% evidence |
| Exact sum: 16.7 + 14.8 + 15.7 + 5 = 52.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20ERIS Lifesciences LtdERIS | 51.6/100Mixed-positive evidence76% evidence | TURNING | 21.0/35 Revenue 9.6% · PAT 62.2% · OPM change -2 pp 95% evidence | 14.1/25 ROCE 14.1% · OPM 34% 76% evidence | 11.1/20 P/E 28.6× · PEG — 50% evidence | 5.4/20 RS sector -13.9% · RS bench -10.4% · 1Y -24.6%0 of 10 weeks ahead 70% evidence |
| Exact sum: 21 + 14.1 + 11.1 + 5.4 = 51.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Akums Drugs & Pharmaceuticals LtdAKUMS | 51.0/100Mixed-positive evidence71% evidence | LEADER | 13.9/35 Revenue 5.9% · PAT -25.3% · OPM change 4 pp 83% evidence | 10.3/25 ROCE 14.9% · OPM 13% 76% evidence | 9.6/20 P/E 38.6× · PEG — 15% evidence | 17.2/20 RS sector 11.1% · RS bench 29.9% · 1Y 24.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 13.9 + 10.3 + 9.6 + 17.2 = 51 · Decision use: Price leads the evidence: RS versus the benchmark is 29.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 22J B Chemicals & Pharmaceuticals LtdJBCHEPHARM | 47.1/100Mixed-negative evidence96% evidence | 11.1/35 Revenue 5.9% · PAT 7.4% · OPM change -2 pp 88% evidence | 19.9/25 ROCE 25.4% · OPM 22% 100% evidence | 3.7/20 P/E 53.8× · PEG 2.34 100% evidence | 12.4/20 RS sector 2.9% · RS bench 23.5% · 1Y 41%6 of 10 weeks ahead 100% evidence | |
| Exact sum: 11.1 + 19.9 + 3.7 + 12.4 = 47.1 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 23Sun Pharmaceutical Industries LtdSUNPHARMA | 46.4/100Mixed-negative evidence100% evidence | BREAKING OUT | 17.8/35 Revenue 11.4% · PAT 16.5% · OPM change -2 pp 100% evidence | 16.3/25 ROCE 20.5% · OPM 29% 100% evidence | 4.0/20 P/E 37.8× · PEG 3.8 100% evidence | 8.3/20 RS sector -4.7% · RS bench 12.3% · 1Y 17.2%7 of 12 weeks ahead 100% evidence |
| Exact sum: 17.8 + 16.3 + 4 + 8.3 = 46.4 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 24Strides Pharma Science LtdSTAR | 46.1/100Mixed-negative evidence80% evidence | FADING | 16.2/35 Revenue 8.1% · PAT 79.1% · OPM change -1 pp 95% evidence | 12.1/25 ROCE 18.3% · OPM 18% 95% evidence | 11.3/20 P/E 16.3× · PEG — 15% evidence | 6.5/20 RS sector -9.2% · RS bench 6.6% · 1Y 12.9%9 of 12 weeks ahead 100% evidence |
| Exact sum: 16.2 + 12.1 + 11.3 + 6.5 = 46.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Torrent Pharmaceuticals LtdTORNTPHARM | 45.5/100Mixed-negative evidence100% evidence | BREAKING OUT | 16.7/35 Revenue 32.9% · PAT 7.7% · OPM change 2 pp 100% evidence | 13.2/25 ROCE 15.2% · OPM 34% 100% evidence | 0.9/20 P/E 87.3× · PEG 5.11 100% evidence | 14.7/20 RS sector 5.4% · RS bench 23.6% · 1Y 41.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 16.7 + 13.2 + 0.9 + 14.7 = 45.5 · Decision use: Price leads the evidence: RS versus the benchmark is 23.6%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 26Biocon LtdBIOCON | 42.5/100Mixed-negative evidence96% evidence | BREAKING OUT | 12.1/35 Revenue 10.9% · PAT -74.2% · OPM change -1 pp 88% evidence | 10.8/25 ROCE 3.6% · OPM 23% 100% evidence | 9.9/20 P/E 178× · PEG 0.82 100% evidence | 9.7/20 RS sector -7.4% · RS bench 9% · 1Y 8%8 of 12 weeks ahead 100% evidence |
| Exact sum: 12.1 + 10.8 + 9.9 + 9.7 = 42.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Mankind Pharma LtdMANKIND | 42.4/100Mixed-negative evidence100% evidence | BREAKING OUT | 17.1/35 Revenue 14.2% · PAT 8% · OPM change 2 pp 100% evidence | 12.6/25 ROCE 13.5% · OPM 26% 100% evidence | 4.9/20 P/E 47.8× · PEG 2.81 100% evidence | 7.8/20 RS sector -11.1% · RS bench 4.9% · 1Y -5.1%10 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 12.6 + 4.9 + 7.8 = 42.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Gufic BioSciences LtdGUFICBIO | 41.9/100Mixed-negative evidence90% evidence | TURNING | 19.6/35 Revenue 15.1% · PAT -8.6% · OPM change 6 pp 88% evidence | 12.6/25 ROCE 12.3% · OPM 19% 100% evidence | 2.0/20 P/E 60.9× · PEG 4.78 100% evidence | 7.7/20 RS sector -18.5% · RS bench 14.8% · 1Y 0.7%9 of 11 weeks ahead 70% evidence |
| Exact sum: 19.6 + 12.6 + 2 + 7.7 = 41.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29Aurobindo Pharma LtdAUROPHARMA | 41.1/100Mixed-negative evidence96% evidence | LEADER | 11.5/35 Revenue 6.1% · PAT 0.6% · OPM change -1 pp 88% evidence | 13.3/25 ROCE 12.8% · OPM 20% 100% evidence | 4.1/20 P/E 25.9× · PEG 2.67 100% evidence | 12.2/20 RS sector 4.4% · RS bench 22.3% · 1Y 40.7%11 of 12 weeks ahead 100% evidence |
| Exact sum: 11.5 + 13.3 + 4.1 + 12.2 = 41.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30Natco Pharma LtdNATCOPHARM | 39.8/100Mixed-negative evidence96% evidence | ASLEEP | 5.1/35 Revenue -8% · PAT -24.6% · OPM change -28 pp 88% evidence | 12.9/25 ROCE 17.1% · OPM 17% 100% evidence | 19.1/20 P/E 11.6× · PEG 0.76 100% evidence | 2.7/20 RS sector -17.3% · RS bench -2.6% · 1Y -5.2%2 of 12 weeks ahead 100% evidence |
| Exact sum: 5.1 + 12.9 + 19.1 + 2.7 = 39.8 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 31Lincoln Pharmaceuticals LtdLINCOLN | 39.4/100Mixed-negative evidence83% evidence | ASLEEP | 11.6/35 Revenue 7.5% · PAT 7.2% · OPM change -3 pp 83% evidence | 14.2/25 ROCE 16.3% · OPM 13% 95% evidence | 9.8/20 P/E 13.2× · PEG — 50% evidence | 3.8/20 RS sector -14.7% · RS bench 0.2% · 1Y 6.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 11.6 + 14.2 + 9.8 + 3.8 = 39.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 32Zim Laboratories LtdZIMLAB | 39.1/100Mixed-negative evidence76% evidence | LEADER | 6.0/35 Revenue -1.2% · PAT -51.9% · OPM change -6.6 pp 83% evidence | 6.1/25 ROCE 4.8% · OPM 6.8% 95% evidence | 8.7/20 P/E 139× · PEG — 15% evidence | 18.3/20 RS sector 16.5% · RS bench 35.4% · 1Y 0%12 of 12 weeks ahead 100% evidence |
| Exact sum: 6 + 6.1 + 8.7 + 18.3 = 39.1 · Decision use: Price leads the evidence: RS versus the benchmark is 35.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 33Suven Life Sciences LtdSUVEN | 38.4/100Thin evidence · provisional58% evidence | TURNING | 18.2/35 Revenue 14.3% · PAT -72% · OPM change -350 pp 65% evidence | 2.1/25 ROCE -76.9% · OPM — 84% evidence | 10.0/20 P/E — · PEG — 0% evidence | 8.1/20 RS sector -30.9% · RS bench 46.4% · 1Y 9.2%11 of 11 weeks ahead 70% evidence |
| Exact sum: 18.2 + 2.1 + 10 + 8.1 = 38.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 34Indoco Remedies LtdINDOCO | 38.2/100Thin evidence · provisional58% evidence | TURNING | 20.4/35 Revenue 11.9% · PAT 100% · OPM change 5 pp 71% evidence | 4.3/25 ROCE 0.9% · OPM 9% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.5/20 RS sector -32.2% · RS bench -9.2% · 1Y -30.8%6 of 10 weeks ahead 70% evidence |
| Exact sum: 20.4 + 4.3 + 10 + 3.5 = 38.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 35Alembic Pharmaceuticals LtdAPLLTD | 38.1/100Mixed-negative evidence90% evidence | TURNING | 14.4/35 Revenue 10.1% · PAT 15.3% · OPM change -3 pp 88% evidence | 6.9/25 ROCE 12.6% · OPM 12% 100% evidence | 12.3/20 P/E 21.4× · PEG 1.74 100% evidence | 4.5/20 RS sector -24.1% · RS bench -4.7% · 1Y -20.1%2 of 11 weeks ahead 70% evidence |
| Exact sum: 14.4 + 6.9 + 12.3 + 4.5 = 38.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 36Bajaj Healthcare LtdBAJAJHCARE | 36.0/100Mixed-negative evidence87% evidence | FADING | 9.9/35 Revenue 12.3% · PAT -59.1% · OPM change 1 pp 95% evidence | 10.4/25 ROCE 11.5% · OPM 17% 95% evidence | 10.8/20 P/E 20.1× · PEG — 50% evidence | 4.9/20 RS sector -26.4% · RS bench -12.1% · 1Y -34.9%2 of 12 weeks ahead 100% evidence |
| Exact sum: 9.9 + 10.4 + 10.8 + 4.9 = 36 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 37Cipla LtdCIPLA | 35.9/100Mixed-negative evidence100% evidence | BREAKING OUT | 4.9/35 Revenue 1.8% · PAT -37.7% · OPM change -9 pp 100% evidence | 11.3/25 ROCE 15.5% · OPM 17% 100% evidence | 12.1/20 P/E 33.2× · PEG 1.25 100% evidence | 7.6/20 RS sector -14.5% · RS bench 1.3% · 1Y -3.9%7 of 12 weeks ahead 100% evidence |
| Exact sum: 4.9 + 11.3 + 12.1 + 7.6 = 35.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 38Bharat Parenterals Ltd541096 | 34.7/100Thin evidence · provisional55% evidence | TURNING | 13.5/35 Revenue 1.5% · PAT 37.5% · OPM change -2.7 pp 62% evidence | 3.5/25 ROCE -1.8% · OPM -0.5% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 7.7/20 RS sector -20.9% · RS bench 17.8% · 1Y -5.2%11 of 11 weeks ahead 70% evidence |
| Exact sum: 13.5 + 3.5 + 10 + 7.7 = 34.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 39Dr Reddys Laboratories LtdDRREDDY | 29.9/100Adverse evidence100% evidence | ASLEEP | 4.1/35 Revenue -0.9% · PAT -44.6% · OPM change -14 pp 100% evidence | 10.7/25 ROCE 13% · OPM 11% 100% evidence | 13.5/20 P/E 29.7× · PEG 1.15 100% evidence | 1.6/20 RS sector -24.3% · RS bench -10.6% · 1Y -10.2%2 of 12 weeks ahead 100% evidence |
| Exact sum: 4.1 + 10.7 + 13.5 + 1.6 = 29.9 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 40Influx Healthtech LtdINFLUX | 65.1/100Thin evidence · provisional50% evidence | BREAKING OUT | 19.1/35 Revenue — · PAT — · OPM change -1 pp 26% evidence | 20.3/25 ROCE 40% · OPM 19% 95% evidence | 10.0/20 P/E 33.4× · PEG — 15% evidence | 15.7/20 RS sector 12.1% · RS bench 31.1% · 1Y 90.7%9 of 12 weeks ahead 70% evidence |
| Exact sum: 19.1 + 20.3 + 10 + 15.7 = 65.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 41Syncom Healthcare LtdSYNCOM | 50.5/100Thin evidence · provisional31% evidence | 17.2/35 Revenue -69.4% · PAT 63.5% · OPM change — 16% evidence | 6.9/25 ROCE -20.2% · OPM -225.7% 46% evidence | 10.0/20 P/E — · PEG — 0% evidence | 16.4/20 RS sector 29.1% · RS bench 45.7% · 1Y —9 of 12 weeks ahead to 2021-06-30 70% evidence | |
| Exact sum: 17.2 + 6.9 + 10 + 16.4 = 50.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 42Fredun Pharmaceuticals Ltd539730 | 47.8/100Thin evidence · provisional49% evidence | ASLEEP | 19.1/35 Revenue — · PAT — · OPM change 4 pp 20% evidence | 14.7/25 ROCE 21.3% · OPM 14% 76% evidence | 9.2/20 P/E 50× · PEG — 15% evidence | 4.8/20 RS sector -45.5% · RS bench 59.4% · 1Y 6.5%2 of 12 weeks ahead 100% evidence |
| Exact sum: 19.1 + 14.7 + 9.2 + 4.8 = 47.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 43Sai Parenterals LtdSAIPARENT | 39.1/100Thin evidence · provisional33% evidence | TURNING | 15.2/35 Revenue — · PAT — · OPM change — 16% evidence | 5.3/25 ROCE 6% · OPM 13% 95% evidence | 8.6/20 P/E 170× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —3 of 3 weeks ahead 0% evidence |
| Exact sum: 15.2 + 5.3 + 8.6 + 10 = 39.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Glenmark Pharmaceuticals Ltd's share price today?
Glenmark Pharmaceuticals Ltd trades at ₹2,234, +8.0% over the past year. The company is valued at ₹63,041 Cr. The stock sits at 71% of its 52-week range of ₹1,812–₹2,406, +6.0% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 60 weeks in. — as of 31 July 2026.
What were Glenmark Pharmaceuticals Ltd's latest quarterly results?
Glenmark Pharmaceuticals Ltd reported revenue of ₹4,018 Cr and net profit of ₹483 Cr for the Jun 26 quarter. Revenue rose 23.1% and profit rose 927.7% year on year. Earnings per share were ₹17.11. The operating margin was 20.0%, 2.0 pp higher than a year earlier. — as of 31 July 2026.
What is Glenmark Pharmaceuticals Ltd's revenue?
Glenmark Pharmaceuticals Ltd reported revenue of ₹4,018 Cr in the Jun 26 quarter, +23.1% year on year. For the full FY26 fiscal year, revenue was ₹16,983 Cr (+27.5%). Over the last 10 years revenue compounded at 8.4% a year. — as of 31 July 2026.
What is Glenmark Pharmaceuticals Ltd's profit?
Glenmark Pharmaceuticals Ltd earned ₹483 Cr of net profit in the Jun 26 quarter, +927.7% year on year — the 4th straight quarter of growth. Full-year FY26 profit was ₹1,362 Cr. The operating margin ran 20.0% in the latest quarter. — as of 31 July 2026.
What is Glenmark Pharmaceuticals Ltd's market cap?
Glenmark Pharmaceuticals Ltd's market capitalisation is ₹63,041 Cr at a share price of ₹2,234. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Glenmark Pharmaceuticals Ltd's P/E ratio?
Glenmark Pharmaceuticals Ltd trades at a P/E of 20.2×, at the 56th percentile of its own 10-year range, against a long-run median of 18.6×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Glenmark Pharmaceuticals Ltd pay a dividend?
Yes — Glenmark Pharmaceuticals Ltd's dividend payout was 5% of profit in FY26, and it recorded a payout in 11 of its last 13 reported fiscal years. One of those years shows a negative ratio because profit itself was negative. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is Glenmark Pharmaceuticals Ltd overvalued?
On its own history, Glenmark Pharmaceuticals Ltd looks mid-range against its own history: its P/E of 20.2× sits at the 56th percentile of its 10-year range (long-run median 18.6×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 31 July 2026.
Is Glenmark Pharmaceuticals Ltd growing?
Yes — Glenmark Pharmaceuticals Ltd is growing: latest-quarter revenue +23.1% year on year, profit +927.7%, and the margin +2.0 pp at 20.0%. The 10-year compound rates are 8.4% (revenue) and 6.2% (profit). The earnings engine currently reads: improving — as of 31 July 2026.
How is Glenmark Pharmaceuticals Ltd performing?
Glenmark Pharmaceuticals Ltd is in a confirmed uptrend, 60 weeks in. Its latest quarter's revenue rose 23.1% and profit rose 927.7% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 13 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is Glenmark Pharmaceuticals Ltd in?
Mixed — no clean majority across the growth curves, ROCE holding at 18.6% — the per-curve reads carry the story. The read comes from the last 12 quarters of growth (revenue growth +32.9% latest, profit growth +927.7% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is Glenmark Pharmaceuticals Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 60 of stage 2), trading +6.0% versus its 200-day average and at 71% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Glenmark Pharmaceuticals Ltd beating the market?
Not lately — on a trailing-13-week view Glenmark Pharmaceuticals Ltd is currently behind the NIFTY 500 (13 weeks and counting; last ahead the week of 2026-06-04), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +203% against the NIFTY 500's +282% — behind the index over the full window. — as of 31 July 2026.
Will Glenmark Pharmaceuticals Ltd's share price go up?
This page publishes no price forecast for Glenmark Pharmaceuticals Ltd. What it measures instead: the share price is ₹2,234, the price is in a confirmed uptrend 60 weeks in. Its P/E of 20.2× sits at the 56th percentile of its own 10-year range. — as of 31 July 2026.
Who owns Glenmark Pharmaceuticals Ltd?
Promoters hold 46.6% of Glenmark Pharmaceuticals Ltd, foreign institutions 20.9%, domestic institutions 18.6% and the public 13.8% (latest quarter). The biggest move on the register over the last two years: Domestic institutions added 4.7 points over 8 quarters. — as of 31 July 2026.
Does Glenmark Pharmaceuticals Ltd have too much debt?
No — Glenmark Pharmaceuticals Ltd's debt-to-equity is 0.06, and operating profit covers the interest bill 22×. FY26 borrowings were ₹594 Cr against equity of ₹10,512 Cr. The returns on this page are earned, not borrowed — as of 31 July 2026.
What is Glenmark Pharmaceuticals Ltd's capex?
Glenmark Pharmaceuticals Ltd spent ₹1,853 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹2,075 Cr, with ₹428 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Glenmark Pharmaceuticals Ltd's cash flow?
Glenmark Pharmaceuticals Ltd generated ₹3,445 Cr of operating cash flow in FY26 and ₹1,370 Cr of free cash flow after ₹2,075 Cr of capital spending. Reported profit that year was ₹1,362 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Glenmark Pharmaceuticals Ltd's profit real cash?
Yes — over the last 3 fiscal years, 116% of Glenmark Pharmaceuticals Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹3,445 Cr against reported profit of ₹1,362 Cr. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is Glenmark Pharmaceuticals Ltd in its business cycle?
Glenmark Pharmaceuticals Ltd's FY26 operating margin was 27.0%, against a 13-year band of 10.0%–27.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 20.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Glenmark Pharmaceuticals Ltd story?
Biggest watch item: margins are the best this company has ever printed — every ratio flatters at record profitability, so the whole story leans on margins holding. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Glenmark Pharmaceuticals Ltd a stock worth studying right now?
This is not investment advice. The machine read: Glenmark Pharmaceuticals Ltd's earnings have outrun its stock. EPS grew +30.0% in a year against a +8.0% price move. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.